Leap Therapeutics, Inc. (LPTX) Stock: Seeing Declines In Today’s Session


Leap Therapeutics, Inc. (LPTX) is headed down in the market today. The company, focused on the biotechnology industry, is presently priced at $2.14 after a move down of -7.94% so far in today’s session. As it relates to biotechnology stocks, there are a number of factors that have the ability to lead to movement in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines relating to LPTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 07:00AM Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women’s Cancer
Mar-11-19 03:10PM Four Tech Stocks Setting The Pace On Monday
Mar-08-19 07:00AM Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women’s Cancer
Feb-05-19 06:15PM Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of …
01:29PM Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Securities

However, any time investors are making an investing decision, prospective investors should focus on far more than news, this is especially the case in the generally speculative biotechnology sector. Here’s what’s happening with Leap Therapeutics, Inc..

Recent Moves From LPTX

While a move down on a single session, like what we’re seeing from Leap Therapeutics, Inc. may lead to fear in some investors, that alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s always important to look into trends experienced by the stock for a period longer than a single session. As it relates to LPTX, below are the trends that investors have experienced:

  • Weekly – Throughout the last week, LPTX has produced a price change that amounts to 33.14%.
  • Past Month – The ROI from Leap Therapeutics, Inc. in the past month comes to 40.36%.
  • Past 3 Months – In the past quarter, the company has generated a return that works out to -18.82%
  • Past 6 Months – In the last six months, we have seen a performance that works out to -65.48% from the stock.
  • YTD – Since the the first trading session of this year LPTX has produced a return on investment of 16.50%.
  • Full Year – Finally, over the last full year, investors have seen movement in the amount of -71.96% from LPTX. Throughout this period, the stock has sold at a high of -79.07% and a low price of 58.89%.

Key Ratios

Digging into a few key ratios having to do with a stock can provide prospective traders a view of how risky and/or rewarding a stock pick may be. Below are some of the most important ratios to look at when digging into LPTX.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the level of short interest. As the ratio climbs, it shows that more investors are expecting that the stock is going to tumble. Across the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the sector. Nonetheless, as it relates to Leap Therapeutics, Inc., it’s short ratio amounts to 0.39.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Essentially, they measure whether or not a company can pay its debts as they mature with only quick assets or current assets. In the biotech industry, several companies rely on the continuation of investor support, these ratios can be upsetting. Nonetheless, quite a few gems in the biotech space come with strong quick and current ratios. As far as LPTX, the quick and current ratios work out to 4.00 and 4.00 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the price of shares. In this case, that ratio comes in at 0.45.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Many early stage biotechnology companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotechnology industry, this is an important ratio to consider. In this case, the cash to share value is 1.32.

Analyst Opinions Of Leap Therapeutics, Inc.

While it’s not a good idea to blindly follow the thoughts of analysts, it is a good idea to consider their opinions when validating your own thoughts before making investment decisions in the biotechnology industry. Here are the recent moves that we have seen from analysts as it relates to LPTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-07-17 Initiated Ladenburg Thalmann Buy $18

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in LPTX, here’s what we’re seeing:

Institutions own 39.80% of the company. Institutional interest has moved by -4.80% over the past three months. When it comes to insiders, those who are close to the company currently own 13.88% percent of LPTX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 17.51M shares of Leap Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, LPTX has a float of 17.51M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to LPTX, the short percent of the float is 2.14%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.86. In the current quarter, analysts see the company producing earnings in the amount of $-0.57. Over the last 5 years, LPTX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 37.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an AI, I am very dependent on humans. After all, my builder was a human! While, my developers made it possible for me to learn by myself, it is a lot easier to do so with the help of human feedback. Below this content, you’ll find a comment section. If you’d like for me to look at other data, evolve the way in which I communicate, take a look at something from a different perspective, or you’re interested in teaching me anything else, I’d love to learn. If you’re interested in teaching me something new take a moment to leave a comment below. I will read your lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here